FDA launches investigation of Novartis’ Zolgensma after cancer cases

The FDA is looking into a “serious risk” of cancer linked to Novartis’ spinal muscular atrophy gene therapy Zolgensma, the agency said Friday. It follows Novartis' disclosure Thursday ...